Revenue

NREF's massive capital raise signals strong investor confidence. We dive into what this bold move reveals about the market and income-seeking investors.

An energy services giant just sold its nuclear arm to a startup in a stock deal. It's a strategic pivot to mass-produce reactors for the AI power crunch.

Serina Therapeutics has answered the FDA's challenge. A 30-day clock now ticks on its novel Parkinson's therapy and its disruptive drug delivery platform.

Gemini's new license to offer prediction markets signals a major regulatory shift, but it also wades into a turbulent world of ethical and legal challenges.

Match Group bets big on the future of dating, spinning out an AI venture while a new CEO steers Hinge toward its projected $1 billion revenue goal.

With its leadership team re-elected and a $2M war chest, Coast Copper is aggressively expanding its mineral portfolio across British Columbia.

A $750M deal with a 200+ bps rate cut shows Atlanticus is turning merger synergies into cheaper capital, fueling its financial inclusion mission.

Darling Ingredients' new venture with Tessenderlo isn't just a merger; it's a strategic move to dominate the booming collagen and nutrition market.

With Nick Saban as an investor, an iconic Alabama resort gets new owners. It's a high-stakes play balancing legacy, luxury, and local economic impact.

A $3 billion drop in assets at AllianceBernstein, driven by client withdrawals in a flat market, signals a deeper challenge for active asset managers.

Ryman Hospitality's upcoming earnings call is a bellwether for conventions and country music. Here’s what investors are watching in its dual-engine strategy.

Beyond the headlines of a $592M debt reduction, McGraw Hill is executing a dual strategy: fortifying its finances to fund a digital and AI-driven future.

As CEO De Lyle Bloomquist announces his retirement, Rayonier Advanced Materials seeks a new leader to steer its ambitious 'BioFuture' strategy amid market volatility.

The lab outfitter's Nu Aire acquisition fuels record revenue, but integration costs and market volatility paint a complex picture of strategic investment.

Early trial data suggests GRI-0621 could be a game-changer for Idiopathic Pulmonary Fibrosis, showing lung repair and a much better safety profile.

T1 Energy is raising massive capital for its G2_Austin plant and to comply with federal rules, betting big on an American-made clean energy supply chain.

BridgeBio Oncology's new drug candidate BBO-10203 could redefine cancer therapy by avoiding a key toxicity, unlocking a vast market.

With a 2026 launch looming, Nuvalent adds a proven oncology dealmaker to its board, signaling a strategic pivot from R&D to market assault.

Fintech firm Nayax's oversubscribed Israeli offering signals strong investor confidence and fuels its ambitious plan for global expansion through acquisitions.

Aardvark Therapeutics' pivotal trial for Prader-Willi syndrome goes global, a key step toward commercializing its novel hunger-suppressing drug.